

Interim management statement

January - March 2024


Johan Forssell

President and CEO

T QI in summary

- Adjusted net asset value SEK 9 I 5bn, + I 2%, all business areas contributed strongly
- Total shareholder return of 15% compared to 8% for the SIXRX return index
- Listed Companies outperformed the Swedish stock market
- Good sales and profit growth in Patricia Industries
- Value increase in Investments in EQT driven by EQT AB
- Strong financial position







Total adjusted assets SEK 923bn Adjusted net asset value SEK 915bn

Listed Companies SEK 625bn 68% of total assets Patricia Industries SEK 203bn 22% of total assets Investments in EQT SEK 93bn 10% of total assets

Listed Companies SEK 625bn 68% of total assets

3

11

Highlights during the quarter – Listed Companies

- AstraZeneca presented positive clinical data, announced strategic acquisitions
- Epiroc announced a split of Tools & Attachments division to ensure strong focus on profitable growth in each business line following the STANLEY Infrastructure acquisition
- Morten Wierod appointed new
 CEO of ABB







ir

Performance – Listed Companies Q1 2024




Patricia Industries SEK 203bn 22% of total assets



ir

Highlights during the quarter – Patricia Industries

- Good organic sales and EBITA growth
- Strong growth in Laborie, supported by Optilume[™] urethral strictures
- Scott Nelson appointed new CEO of BraunAbility
- Strong total return










Valuation methodology for estimated market values Peer companies valuation, illustration with SIXRX



18% total return


Driven by + Multiple expansion + Earnings growth + Currency

Operating performance – Major subsidiaries QI 2024



T EBITDA – Patricia Industries

LTM sales: SEK 63.6bn EBITDA: SEK 15.6bn



Quarterly


LTM (RHS)

Reported EBITDA, including items affecting comparability, for subsidiaries and Tre Skandinavien (40 percent ownership). For Mölnlycke, Q3 2020-Q3 2021 were materially positively impacted by PPE contracts. Q4 2018 negatively impacted by one-time Swedish tax authority decision relating to Tre Skandinavien. **T** Operating performance – Major subsidiaries

	Value, SEK bn	Organic growth, % Q1 2024		Margins, % Q1 2024	Change vs. Q1 2023
Laborie	23.7	21	ebitda Ebita	28.2 26.7	-1.1 -0.8
perm _o bil	17.5	10	ebitda Ebita	21.8 18.4	3.8 4.3
ADVANCED INSTRUMENTS	12.7	7	ebitda Ebita	40.3 38.2	4.3 4.2
sarnova	19.3	б	ebitda Ebita	5. 3.	1.4 1.3
BraunAbility	9.8	б	ebitda Ebita	3.2 .3	0.1 0.2
↔● Mölnlycke®	93.3	5	ebitda Ebita	29.4 25.3	1.1 0.3
Piab group	10.9	-3	ebitda Ebita	26.7 22.4	-1.8 -2.7
TATLAS ANTIBODIES	1.9	-30	ebitda Ebita	40.0 29.8	-8.4 -11.9
Vectura ×	4.6	74*			



İ Mölnlycke



Group

- Organic sales growth amounted to 5 percent in constant currency, mainly driven by Wound Care and ORS, while Gloves declined.
- The EBITDA margin increased compared to last year, supported by volume growth and lower raw materials costs, partly offset by increased logistics costs related to the Red Sea conflict. The EBITA margin was negatively affected by one-off costs related to the relocation of Gloves production in Malaysia.

Wound Care

- Organic sales growth amounted to 6 percent in constant currency, with growth across all geographies.
- After the end of the quarter, Mölnlycke signed an agreement to acquire P.G.F. Industry Solutions GmbH, an Austrian manufacturer of the Granudacyn® wound moisturizing solutions sold under the Mölnlycke brand.

Operating Room Solutions

• Organic sales growth amounted to 4 percent in constant currency, driven by volume growth, mix and price, however negatively impacted by supply chain delays to the Middle East markets, as a consequence of the Red Sea conflict. The Trays category remains the main driver.

Gloves

%

35

30

25

20

15

10

5

n


- Organic sales growth amounted to -5 percent in constant currency, mainly due to supply chain delays as a consequence from the Red Sea conflict. Sales in the US market were essentially flat.
- To improve efficiency and further reduce the environmental footprint, Mölnlycke announced the closure of one plant in Malaysia, consolidating production to the existing, more sustainable facilities.
- Mölnlycke was awarded a 4-year Biogel contract in Sweden, where sustainability was a key differentiator.

Antiseptics

• Organic sales growth amounted to 27 percent in constant currency, supported by a stable supply situation.



Laborie



Optilume™ Urethral strictures

- Strong sales growth, exceeding plan
- High gross margin product contributing significantly to group profitability

Optilume™ BPH (Benign Prostatic Hyperplasia)

- Recently launched, encouraging initial commercial uptake
- Significant market potential
- Substantial investments in clinical studies, sales and marketing initialives




Investments in EQT SEK 93bn 10% of total assets



- EQT Funds 0%

Net cash flow to Invest Receive SEK - I bn





<u>Grow net asset value</u>

+20% average annual growth, 5 years (SIXRX I 4%)

Pay a steadily rising dividend

+9% average annual growth, 10 years

Deliver on our ESG targets

Climate & Resource Efficiency Diversity & Inclusion Business Ethics & Governance

Strategic Priorities – Highlights

Business Elhics & Governance Climate & Resource Efficiency **Diversity & Inclusion 65%** 37% 100% (2022: 57%) (2022: 33%)(2022: 96%) Average share Reduction of Share of our portfolio of females in scope 1&2 GHG companies that conduct portfolio companies' emissions in regular anti-corruption portfolio, vs. 2016 boards Iraining

Deliver on our ESG targets

Priorities 2024

Future-proof our companies to drive sustainable profit growth while never compromising on efficiency

Use financial strength to capture investment opportunities



Driving Value Creation Proven business model and clear strategic direction

Portfolio of industry leaders with strong profitability and high exposure to secular growth

Strong balance sheet and cash flow generation



Helena Saxon

CFO

Grow net asset value 20% average annual growth, with dividend SEK 915bn, adjusted added back, 5 years net asset value, SEK bn (SIXRX | 4%) March 31, 2024 1 000 800 600 400 200 0 2017 2018 2019 2020 202 I 2022 2023 2024

-200


Listed companies

s Patricia Industries

Investments in EQT


Other assets & liabilities


Total return by business area




i

Listed companies – Total return and NAV contribution, Q1 2024





Patricia Industries - major drivers of estimated market values QI 2024






QI 2024

ir

Patricia Industries – change in estimated market values






Financial development

Ensuring financial strength and maximizing investment capacity

Leverage in the lower end of the range

AA-/Aa3 ratings S&P/Moody's






Debt maturity profile


SEK m

Average maturity 10.6 years



ir

Average annual total return, March 31, 2024







permobil

Invest Receive ABQI Presentation: Permobil Group

April 18th 2024





Bengt Thorsson

CEO and President of Permobil Group

Our foundation is from 1967, we focus on solving our users' needs

66

Every person has the right to have his or her disability compensated as far as possible by aids with the same technical standard as those we all use in our everyday lives.

Dr. Per Udden Founder -1967

We don't forget our past; we look to the future. What we do is innovate for individuals






We support individuals to live their lives to the fullest by developing the world's most advanced assistive technology solutions



We make a difference every day by innovaling for individuals

Example of how we innovate for individuals

The design and functionality of the Explorer Mini aid the development of...








Industry trends

The fundamental economic indicators of GDP and healthcare spending correlate strongly with the market for complex rehab technology

The underlying demand is growing, our industry is projected to grow in line with global healthcare expenditures



Healthcare expenditure per capita (USD)

Note: Healthcare expenditures are based on the latest available data, varying between 2022-2021. US healthcare expenditures have been adjusted for illustrative clarity Source: World Health organization, The World Bank, OECD, Permobil analysis Directional

Multiple market archetypes, the majority of our business go through dealer markets



permobil

Distributor market

Permobil sells through distributors in markets where we don't have our own sales force




Examples of markets:



Dealer market

In a majority of Permobil's key markets we sell through a dealer, who has direct relationships with payers, clinicians and end-users




Examples of markets:



Tender market

In tender markets Permobil collects reimbursement directly from payers






41

I O key trends are driving change across the healthcare ecosystem and shaping the future landscape of complex rehab lechnology









Inflation and cost pressures



Growing focus on sustainability





Consolidation across healthcare value chain

$\Xi(\$)$

Evolving payment models and value based models

Í	Ċ	
-		-

Changing sites of care/point of cale



Technological advancement (hardware)




Big data, AI/ML, and digital Ísoftware



World leader in complex rehab technology

We offer products and services tailored to meet our users' needs Permobil's portfolio





All Insurance and Loan represent half of our business, the US is our largest market Permobil's business split



Insurance and Loan represent ~50% of the business, *revenue split per product category*

We have a global footprint, the US is our largest market






Accelerated growth under Patrica Industries' ownership

Permobil financial development since 2013


Our growth is a result of innovation, our go to market, a decentralized operating model and strategic acquisitions

Profit margin expansion of ~4 pp. since 2018


I) Other incl. 3rd party products , mergers and acquisitions Source: Reported financials for 2023, adjusted EBIT-margin



Complementary acquisitions to drive geographical expansion, segment expansion, portfolio



Nearly all offerings across regions experienced YoY growth in 2023 Revenue growth 2023 vs 2022



Excluding revenue from 3rd party products, mergers and acquisitions

Resilient profitable growth every quarter since Q3 2022

Financials per quarter reported


Revenue, reported

Note:




SEKm **5 000** . 1 500 000 500 0 QI Q2 Q3 Q4 2022 2023 2024 Year 202 I

Adj. EBITA¹



We continue to deliver profitable growth in QI 2024

Financial performance QI 2024



CONFIDENTIAL EBITA adjustments include non-recurring items e.g., M&A transaction costs and special projects

50



Our plans for 2024 and beyond

In 2024, we will launch our new R&D and production site in Sundsvall

Example of what we will do in 2024

We have collaborated with the Patricia Industries - owned Vectura in the design and development of our new site, our ambition is to be the leader in accessibility







We continue to invest in R&D and accelerate our focus on digital capabilities Example of what we will do in 2024





We have shifted our new product development from mainly hardware mechanics...



Chassis mechanics

... and are now accelerating our efforts in digitalization and connectivity



Electronics and mechatronics



Wheel mechanics



Mechanical control and steering




Digital platform, connectivity and artificial intelligence



Software engineering and UX

Beyond 2024, we will maintain our focus on our users and further strengthen our position **T**



Innovating for individuals





İ

Financial calendar

May 7, 2024 Annual General Meeting

July 17, 2024 Interim Report January-June 2024

October 17, 2024 Interim Management Statement January-September 2024

January 23, 2025 Year-End Report 2024



Jacob Lund

Chief Communications & Sustainability Officer +46 725 60 21 57 Jacob.lund@investreceive.com

Magnus Dalhammar

Head of Invest Receive Relations +46 73 524 2130 Magnus.dalhammar@investreceive.com